Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report
- PMID: 27565931
- DOI: 10.1016/j.lungcan.2016.07.001
Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report
Abstract
Immune checkpoint inhibitor is a verified standard of care as a second-line chemotherapy for non-small cell lung cancer. Management of immune-related adverse effects (irAEs) is crucial for ensuring patient safety. However, less frequent irAEs may result in complications. Here, we report a patient with recurrent lung adenocarcinoma who was treated with nivolumab and developed immune-related pancreatitis. A 66-year-old Japanese female with recurrent lung adenocarcinoma and metastatic lymph nodes presented with anorexia, vomiting, and back pain on day 18 of two cycles of nivolumab. Laboratory data demonstrated a grade 3 elevation of serum amylase and lipase levels. Initially, no abnormality could be detected on computed tomography (CT), magnetic resonance cholangiopancreatography (MRCP), or the Gallium scan. The patient was treated with high-dose prednisone, resulting in gradual improvement of symptoms and laboratory data. A follow-up MRCP revealed a swollen pancreas and pancreatic inflammation. Immune-related pancreatitis is a rare type of nivolumab-induced irAE that shows no significant changes on radiologic imaging, except for a swollen pancreas on CT, and can be suppressed using high-dose prednisone.
Keywords: Immune-checkpoint inhibitor; Immune-related pancreatitis; Lung adenocarcinoma; Nivolumab.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.J Med Case Rep. 2019 Mar 26;13(1):88. doi: 10.1186/s13256-019-2002-2. J Med Case Rep. 2019. PMID: 30909965 Free PMC article. Review.
-
Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.J Med Case Rep. 2019 Oct 24;13(1):316. doi: 10.1186/s13256-019-2245-y. J Med Case Rep. 2019. PMID: 31647029 Free PMC article. Review.
-
Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma.Lung Cancer. 2018 May;119:21-24. doi: 10.1016/j.lungcan.2018.02.018. Epub 2018 Mar 2. Lung Cancer. 2018. PMID: 29656748
-
Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.J Oncol Pharm Pract. 2019 Mar;25(2):487-491. doi: 10.1177/1078155217738325. Epub 2017 Oct 25. J Oncol Pharm Pract. 2019. PMID: 29067858
-
FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.World J Surg Oncol. 2016 Sep 5;14(1):238. doi: 10.1186/s12957-016-0998-y. World J Surg Oncol. 2016. PMID: 27595749 Free PMC article.
Cited by
-
Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors.Eur J Radiol. 2020 Nov;132:109275. doi: 10.1016/j.ejrad.2020.109275. Epub 2020 Sep 10. Eur J Radiol. 2020. PMID: 32949913 Free PMC article.
-
Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study.J Clin Med Res. 2019 Apr;11(4):225-236. doi: 10.14740/jocmr3750. Epub 2019 Mar 18. J Clin Med Res. 2019. PMID: 30937112 Free PMC article. Review.
-
Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy.Gastroenterol Rep (Oxf). 2019 Dec 17;8(1):25-30. doi: 10.1093/gastro/goz065. eCollection 2020 Feb. Gastroenterol Rep (Oxf). 2019. PMID: 32104583 Free PMC article. Review.
-
Immune Checkpoint Inhibitor-induced Pancreatitis with Pancreatic Enlargement Mimicking Autoimmune Pancreatitis: A Case Report and Review of the Literature.Intern Med. 2024 Mar 15;63(6):791-798. doi: 10.2169/internalmedicine.1943-23. Epub 2023 Aug 2. Intern Med. 2024. PMID: 37532549 Free PMC article. Review.
-
Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment.Oncologist. 2020 Feb;25(2):105-111. doi: 10.1634/theoncologist.2018-0162. Epub 2019 Sep 9. Oncologist. 2020. PMID: 32043797 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
